Skip to content (Press Enter)
info@gmbpc.rs
  • Who We Are
  • Our Services
    • We have expertize for
    • Medicinal Products
    • Quality and GxP
    • Medical devices
    • Food Supplements
    • Cosmetics
    • Biocides
    • Clinical Support
    • Market Access
    • Supplier Management
    • PMS Support
  • Blog
  • Contact Us
GMB Pharma Consulting

GMB Pharma Consulting

Consultancy and solutions provider of risk management and compliance services to Life Sciences Industry

  • Who We Are
  • Our Services
    • We have expertize for
    • Medicinal Products
    • Quality and GxP
    • Medical devices
    • Food Supplements
    • Cosmetics
    • Biocides
    • Clinical Support
    • Market Access
    • Supplier Management
    • PMS Support
  • Blog
  • Contact Us
GMB Pharma Consulting

GMB Pharma Consulting

Consultancy and solutions provider of risk management and compliance services to Life Sciences Industry

  • Who We Are
  • Our Services
    • We have expertize for
    • Medicinal Products
    • Quality and GxP
    • Medical devices
    • Food Supplements
    • Cosmetics
    • Biocides
    • Clinical Support
    • Market Access
    • Supplier Management
    • PMS Support
  • Blog
  • Contact Us
  • Who We Are
  • Our Services
    • We have expertize for
    • Medicinal Products
    • Quality and GxP
    • Medical devices
    • Food Supplements
    • Cosmetics
    • Biocides
    • Clinical Support
    • Market Access
    • Supplier Management
    • PMS Support
  • Blog
  • Contact Us
info@gmbpc.rs

MDR

2 Results
23.03.202627.04.2026

MIR PDF 7.3.1 (update 23 March 2026)New MIR form – mandatory as from 1st May 2026

Medical device companies in the EU should take a note:the updated MIR (Manufacturer Incident Report) form version 7.3.1, published on 23 March 2026, becomes mandatory from 1 May 2026. This …

Read More
03.02.202621.04.2026

MDR 2026 Revision: New Expectations for Phthalates and CMR Substances – What Manufacturers Need to Know

As of 1 January 2026, an important update to the Regulation (EU) 2017/745 (MDR) reinforces how manufacturers must assess hazardous substances in medical devices—especially phthalates, CMR, and endocrine-disrupting substances.This is …

Read More

Recent Posts

  • EFSA 2026 Update: Revision of Botanical Guidance and Stricter EU Approach to Herbal Ingredients
  • Izmene u načinu podnošenja zahteva za stručna mišljenja za medicinska sredstva
  • MIR PDF 7.3.1 (update 23 March 2026)New MIR form – mandatory as from 1st May 2026
  • EU Cosmetics Regulation Updates 2025–2026: New CMR Restrictions You Can’t Ignore
  • BPC Opinion on ethanol (February 2026)
© Copyright 2026 GMB Pharma Consulting. All Rights Reserved. CoachPress Lite | Developed By Blossom Themes. Powered by WordPress.